Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Prevention and treatment of thromboembolic disorders
US9539218B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539218-B2 |
| Application number | US-88321806-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2006 |
| Priority date | Jan 31, 2005 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a thromboembolic disorder comprising administering a direct factor Xa inhibitor that is 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide no more than once daily for at least five consecutive days in a rapid-release tablet to a patient in need thereof, wherein the thromboembolic disorder is selected from the group consisting of pulmonary embolisms, deep vein thromboses, and stroke. 2. The method of claim 1 , wherein the thromboembolic disorder is pulmonary embolisms. 3. The method of claim 1 , wherein the thromboembolic disorder is deep vein thromboses. 4. The method of claim 1 , wherein the thromboembolic disorder is stroke.
Assignees
Inventors
Classifications
Drugs for disorders of the blood or the extracellular fluid · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Vasodilators for multiple indications · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9539218B2 cover?
- The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
- Who is the assignee on this patent?
- Misselwitz Frank, Kubitza Dagmar, Park Son-Mi, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).